Replimune Group (NASDAQ:REPL) Given New $48.00 Price Target at SVB Leerink

Replimune Group (NASDAQ:REPLGet Rating) had its price target reduced by SVB Leerink from $49.00 to $48.00 in a research report sent to investors on Friday, Stock Target Advisor reports. They currently have an outperform rating on the stock. SVB Leerink also issued estimates for Replimune Group’s Q1 2023 earnings at ($0.61) EPS and Q2 2023 earnings at ($0.62) EPS.

A number of other research firms also recently issued reports on REPL. BMO Capital Markets reduced their price target on shares of Replimune Group from $51.00 to $30.00 and set an outperform rating on the stock in a research note on Friday, March 18th. Piper Sandler reduced their price target on shares of Replimune Group from $52.00 to $44.00 in a research note on Thursday. JPMorgan Chase & Co. reduced their price target on shares of Replimune Group from $47.00 to $39.00 and set an overweight rating on the stock in a research note on Monday, April 4th. Finally, Zacks Investment Research raised shares of Replimune Group from a sell rating to a hold rating in a research note on Saturday, May 14th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of Buy and a consensus target price of $46.83.

Shares of REPL stock opened at $14.79 on Friday. The company has a quick ratio of 23.39, a current ratio of 23.39 and a debt-to-equity ratio of 0.06. The firm’s 50-day moving average is $16.74 and its two-hundred day moving average is $21.67. Replimune Group has a 12 month low of $13.05 and a 12 month high of $40.22.

In other Replimune Group news, major shareholder Fund Iv L.P. Omega sold 16,500 shares of the business’s stock in a transaction that occurred on Monday, March 14th. The shares were sold at an average price of $15.42, for a total transaction of $254,430.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Philip Astley-Sparke sold 9,632 shares of the company’s stock in a transaction on Monday, May 16th. The shares were sold at an average price of $14.59, for a total transaction of $140,530.88. Following the completion of the transaction, the chief executive officer now owns 1,401,080 shares of the company’s stock, valued at approximately $20,441,757.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 39,399 shares of company stock worth $588,526. 40.30% of the stock is owned by insiders.

Several institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its holdings in shares of Replimune Group by 2.3% in the 4th quarter. BlackRock Inc. now owns 2,137,118 shares of the company’s stock valued at $57,915,000 after buying an additional 48,263 shares in the last quarter. State Street Corp raised its position in Replimune Group by 36.6% in the 1st quarter. State Street Corp now owns 1,712,037 shares of the company’s stock valued at $29,070,000 after purchasing an additional 458,420 shares during the last quarter. Vanguard Group Inc. raised its position in Replimune Group by 5.3% in the 1st quarter. Vanguard Group Inc. now owns 1,625,758 shares of the company’s stock valued at $27,606,000 after purchasing an additional 81,845 shares during the last quarter. Emerald Advisers LLC raised its position in Replimune Group by 14.6% in the 1st quarter. Emerald Advisers LLC now owns 1,134,012 shares of the company’s stock valued at $19,256,000 after purchasing an additional 144,054 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust raised its position in Replimune Group by 5.8% in the 4th quarter. Emerald Mutual Fund Advisers Trust now owns 1,075,464 shares of the company’s stock valued at $29,145,000 after purchasing an additional 58,527 shares during the last quarter. Institutional investors and hedge funds own 75.42% of the company’s stock.

Replimune Group Company Profile (Get Rating)

Replimune Group, Inc, a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma.

Read More

Analyst Recommendations for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.